NEW YORK (GenomeWeb) – 23andMe said today that it has received FDA clearance for a genetic health risk report for a syndrome associated with a higher risk of developing hereditary colorectal cancer.

The clearance enables 23andMe to report on the two most common variations in the MUTYH gene influencing MUTYH-associated polyposis (MAP), which confers a high risk for developing large numbers of pre-cancerous polyps, in turn increasing the risk for the development of CRC.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.